These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 16635750)
1. FTY720 treatment of kidney transplant patients: a differential effect on B cells, naïve T cells, memory T cells and NK cells. Vaessen LM; van Besouw NM; Mol WM; Ijzermans JN; Weimar W Transpl Immunol; 2006 Apr; 15(4):281-8. PubMed ID: 16635750 [TBL] [Abstract][Full Text] [Related]
2. FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors. Böhler T; Waiser J; Schuetz M; Neumayer HH; Budde K Nephrol Dial Transplant; 2004 Mar; 19(3):702-13. PubMed ID: 14767029 [TBL] [Abstract][Full Text] [Related]
3. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441 [TBL] [Abstract][Full Text] [Related]
4. FTY720 mediates apoptosis-independent lymphopenia in human renal allograft recipients: different effects on CD62L+ and CCR5+ T lymphocytes. Böhler T; Waiser J; Schütz M; Dragun D; Neumayer HH; Budde K Transplantation; 2004 May; 77(9):1424-32. PubMed ID: 15167602 [TBL] [Abstract][Full Text] [Related]
5. Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients. Johnson TA; Evans BL; Durafourt BA; Blain M; Lapierre Y; Bar-Or A; Antel JP J Immunol; 2011 Jul; 187(1):570-9. PubMed ID: 21622858 [TBL] [Abstract][Full Text] [Related]
6. FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. Yopp AC; Fu S; Honig SM; Randolph GJ; Ding Y; Krieger NR; Bromberg JS J Immunol; 2004 Jul; 173(2):855-65. PubMed ID: 15240672 [TBL] [Abstract][Full Text] [Related]
7. FTY720 markedly increases alloengraftment but does not eliminate host anti-donor T cells that cause graft rejection on its withdrawal. Taylor PA; Kelly RM; Bade ND; Smith MJ; Stefanski HE; Blazar BR Biol Blood Marrow Transplant; 2012 Sep; 18(9):1341-52. PubMed ID: 22728248 [TBL] [Abstract][Full Text] [Related]
8. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Mehling M; Lindberg R; Raulf F; Kuhle J; Hess C; Kappos L; Brinkmann V Neurology; 2010 Aug; 75(5):403-10. PubMed ID: 20592255 [TBL] [Abstract][Full Text] [Related]
9. CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720. Henning G; Ohl L; Junt T; Reiterer P; Brinkmann V; Nakano H; Hohenberger W; Lipp M; Förster R J Exp Med; 2001 Dec; 194(12):1875-81. PubMed ID: 11748287 [TBL] [Abstract][Full Text] [Related]
10. A novel immunosuppressant, FTY720, induces peripheral lymphodepletion of both T- and B cells and immunosuppression in baboons. Quesniaux V; Fullard L; Arendse H; Davison G; Markgraaff N; Auer R; Ehrhart F; Kraus G; Schuurman HJ Transpl Immunol; 1999 Sep; 7(3):149-57. PubMed ID: 10608298 [TBL] [Abstract][Full Text] [Related]
11. FTY720 and central memory: out of sight, out of mind. Slavin AJ; Zamvil SS Neurology; 2010 Aug; 75(5):388-9. PubMed ID: 20610831 [No Abstract] [Full Text] [Related]
12. Prevention, but not cure, of autoimmune diabetes in a NOD.scid transfer model by FTY720 despite effective modulation of blood T cells. Morris MA; McDuffie M; Nadler JL; Ley K Autoimmunity; 2011 Mar; 44(2):115-28. PubMed ID: 20695767 [TBL] [Abstract][Full Text] [Related]
13. FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs. Hofmann M; Brinkmann V; Zerwes HG Int Immunopharmacol; 2006 Dec; 6(13-14):1902-10. PubMed ID: 17161343 [TBL] [Abstract][Full Text] [Related]
14. The novel immunosuppressant FTY720 induces peripheral lymphodepletion of both T- and B-cells in cynomolgus monkeys when given alone, with Cyclosporine Neoral or with RAD. Quesniaux VF; Menninger K; Kunkler A; Vedrine C; Bernhard M; Hedinger R; Kraus G; Schuurman HJ Transpl Immunol; 2000 Nov; 8(3):177-87. PubMed ID: 11147698 [TBL] [Abstract][Full Text] [Related]
15. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis]. García-Merino JA; Sánchez AJ Rev Neurol; 2012 Jul; 55(1):31-7. PubMed ID: 22718407 [TBL] [Abstract][Full Text] [Related]
16. Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients. Böhler T; Schütz M; Budde K; Neumayer HH; Waiser J Int Immunopharmacol; 2007 Jan; 7(1):88-95. PubMed ID: 17161821 [TBL] [Abstract][Full Text] [Related]
17. Prolongation of concordant xenograft survival by treatment with FTY720. Miyata Y; Ohdan H; Noriyuki T; Shintaku S; Shibata S; Yamamoto H; Fan XH; Fudaba Y; Yoshioka S; Asahara T; Fukuda Y; Dohi K Transplant Proc; 1998 Dec; 30(8):4163-5. PubMed ID: 9865334 [No Abstract] [Full Text] [Related]